ChiCTR1900024275 版本V1.0 版本创建时间2019/10/09 22:05:05 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900024275 

最近更新日期:

Date of Last Refreshed on:

2019-07-04 20:09:44 

注册时间:

Date of Registration:

2019-07-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

徐菁鸿医师:该研究尚未获得伦理委员会批准。请于批准后再开始纳入参试者,并与我们联系上传批件。 稳定期COPD患者呼吸肌结构及功能变化的研究

Public title:

Changes of respiratory muscles' structure and function in the patients in stable phase of COPD

注册题目简写:

English Acronym:

研究课题的正式科学名称:

稳定期COPD患者呼吸肌结构及功能变化的研究

Scientific title:

Changes of respiratory muscles' structure and function in the patients in stable phase of COPD

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐菁鸿 

研究负责人:

陈斌 

Applicant:

Jinghong Xu 

Study leader:

Bin Chen  

申请注册联系人电话:

Applicant telephone:

+86 19858735853

研究负责人电话:

Study leader's telephone:

+86 13857720293

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

491560261@qq.com

研究负责人电子邮件:

Study leader's E-mail:

doctorchbe@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省温州市瓯海区南白象街道上蔡村

研究负责人通讯地址:

浙江省温州市瓯海区南白象街道上蔡村

Applicant address:

Shangcai Village, Nanbaixiang Street, Ouhai District, Wenzhou, Zhejiang

Study leader's address:

Shangcai Village, Nanbaixiang Street, Ouhai District, Wenzhou, Zhejiang

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

温州医科大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Wenzhou Medical University

研究负责人所在单位:

温州医科大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Wenzhou Medical University

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

温州医科大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Wenzhou Medical University

研究实施负责(组长)单位地址:

浙江省温州市瓯海区南白象街道上蔡村

Primary sponsor's address:

Shangcai Village, Nanbaixiang Street, Ouhai District, Wenzhou, Zhejiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

温州

Country:

China

Province:

Zhejiang

City:

Wenzhou

单位(医院):

温州医科大学附属第一医院

具体地址:

瓯海区南白象街道上蔡村

Institution
hospital:

The First Affiliated Hospital of Wenzhou Medical University

Address:

Shangcai Village, Nanbaixiang Street, Ouhai District

经费或物资来源:

自筹

Source(s) of funding:

Self-financing.

Target disease:

chronic obstructive pulmonary disease

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

1.探索COPD患者膈肌硬度的变化;2.探索COPD最佳的呼吸肌超声诊断指标;3.探索影响COPD患者生活质量的因素。  

Objectives of Study:

1.To investigate changes of diaphragm stiffness in the patients of COPD; 2.To explore the best ultrasonic index of respiratory muscles to diagnose COPD; 3.To evaluate the influential factors of the quality of life in the patients of COPD.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

年龄50-80岁、BMI18.5-30kg/m2、近1个月无呼吸道感染史的稳定期COPD患者或健康成年人。

Inclusion criteria

The patients in stable phase of COPD or healthy volunteers who are 50-80 years old, 18.5-30 kg/m2 and no respiratory infections last 30 days will be enrolled in the study.

排除标准:

(1)慢性代谢性疾病;
(2)神经或肌肉疾病;
(3)心脏疾病;
(4)近6个月使用过影响骨骼肌的药物;
(5)近3个月有胸、腹部手术史;
(6)气胸、胸腔积液或合并肺结核,支气管扩张,肺间质纤维化等严重呼吸系统疾病;
(7)精神异常或研究者判断因其他原因不适合参加该研究的试验者。

Exclusion criteria:

(1) chronic metabolic disorders;
(2) neurological diseases or muscle diseases;
(3) heart diseases;
(4) took any drugs influencing skeletal muscles in the past 6 months;
(5) a history of surgery in the past 3 months;
(6) pneumothorax, pleural effusion, tuberculosis, bronchiectasis, pulmonary fibrosis or other serious respiratory diseases;
(7) mentally disabled or subject insuitable to the study according to researchers.

研究实施时间:

Study execute time:

From 2019-08-01 00:00:00 To 2021-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-08-01 00:00:00 To 2020-07-15 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

肺功能检测

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Pulmonary Function Test

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

膈肌剪切波速度值、厚度、移动度、肋间肌厚度等超声指标。

Index test:

Ultrasound index: diaphragm shear wave velocity, thickness, mobility, thickness of intercostal muscle.

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

COPD患者

例数:

Sample size:

100

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

The patients in stable phase of COPD

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

健康成年人

例数:

Sample size:

50

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

Healthy volunteers

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

温州 

Country:

China 

Province:

Zhejiang 

City:

Wenzhou 

单位(医院):

温州医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Wenzhou Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肺功能

指标类型:

主要指标

Outcome:

lung function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膈肌剪切波速度值

指标类型:

主要指标

Outcome:

diaphragm shear wave velocity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肋间肌厚度

指标类型:

主要指标

Outcome:

intercostal muscle thickness

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量评分

指标类型:

主要指标

Outcome:

life quality score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

营养指标

指标类型:

主要指标

Outcome:

nutritional indexs

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膈肌厚度

指标类型:

次要指标

Outcome:

diaphragm thickness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膈肌移动度

指标类型:

次要指标

Outcome:

diaphragm excursion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

下肢肌肉厚度

指标类型:

次要指标

Outcome:

thickness of muscles of Lower limbs

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

下肢肌肉横截面积

指标类型:

次要指标

Outcome:

CSA of muscles of Lower limbs

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SEN, SPE, ACC, PPV, NPV, AUC of ROC

指标类型:

主要指标

Outcome:

SEN, SPE, ACC, PPV, NPV, AUC of ROC

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台, http://www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, http://www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-07-04 20:09:44